Developer docs
API playgroundTry for free, no card

Search company profiles

Integrity Bio

Full company profile

uuid000b2s6

Namestring
Integrity Bio
Legal namestring
Curia Global, Inc.
Company typeenum
Private
Founded yearint
1990
Descriptiontext

Integrity Bio is a privately held US biopharmaceutical services company headquartered in Camarillo, California, founded in 2003. The firm positions itself as a leader in protein formulation development, operating in a narrow specialty niche within the broader contract development and manufacturing (CDMO) services landscape. With 101–250 employees, Integrity Bio is mid-sized relative to large integrated CDMOs and competes on scientific depth in protein formulation rather than on end-to-end platform breadth.

The company's core offering centers on protein formulation development services for biopharma clients, a discipline that requires specialized expertise in protein stability, characterization, and delivery. Leadership comprises Michael Reilly as Chief Executive Officer and Byeong Chang as Founder and Chief Scientific Officer, indicating a founder-led scientific governance model with the founder retained in a senior technical role—an arrangement typical of specialist services firms that compete on accumulated technical know-how. The company is privately held with no public listing, no disclosed parent company, and no recorded subsidiaries in the provided data.

The business model follows a professional services / contract services pattern standard to biopharma formulation providers: revenue is generated through project-based formulation development engagements with biotech and pharmaceutical clients. The company maintains a single disclosed site in Camarillo and does not advertise a multi-region facility footprint. No customer logos, pricing model, funding history, M&A activity, or product launches are disclosed in the available data, which limits visibility into revenue mechanics, customer mix, and capital structure. The current data set suggests an established, specialist services firm with stable leadership and a defensible technical niche, but the absence of disclosed financials or strategic activity means any growth or expansion assessment is necessarily constrained.

Short descriptiontext

Integrity Bio is a privately held Camarillo, California-based biopharmaceutical services firm founded in 2003, specializing in protein formulation development for biotech and pharma clients, with 101–250 employees and founder-led scientific leadership.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCamarillo, United States
HQ citystring
Camarillo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
protein formulation development, biopharmaceutical contract services, therapeutic protein services, formulation development services, biologics formulation services
Industry3 codes
PRIMARYHLAAAJAI
Bioprocess Consumables & Reagents (resins, membranes, media components, buffers)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAGAIAG
Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers)
SECONDARYHLAAAJAD
Process Analytical Technology (PAT) & In-Line/At-Line Analytics (spectroscopy, sensors, monitoring)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Formulation Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

Curia generates revenue through providing integrated CDMO services across drug discovery, development, and manufacturing. Services are contracted on a project basis with clients ranging from early-stage biotech to large pharmaceutical companies. Revenue is derived from service fees, manufacturing fees, and potentially milestone payments.

curiaglobal.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Gemagique® AMPS Polymers
Description

Fine chemical polymer product line

curiaglobal.com
+1 more record
Core offering1 text field

Integrity Bio is a privately held protein formulation development company that provides specialized contract services to biopharmaceutical clients. Founded in 2003 and based in Camarillo, California, the company focuses on developing formulations for protein-based therapeutics, supporting drug development and manufacturing pipelines for its biopharma customers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Curia Global is a global Contract Development and Manufacturing Organization (CDMO) offering integrated pharmaceutical services across four main verticals: Small Molecule (discovery through manufacturing), Generic APIs, Biologics (discovery through GMP), and Sterile Drug Product. The company operates 20+ facilities across North America, Europe, and India with 3,000+ professionals. Services include specialized offerings such as mRNA/LNP formulation, high potency API manufacturing, fermentation, flow chemistry, and analytical testing. The Fine Chemicals product line includes specialty reagents like T3P and Gemagique polymers.

Product and service1 record
1Protein Formulation Development
CategoryFormulation Development Services
Description

Contract service offering focused on protein formulation development for biopharmaceutical clients developing protein-based therapeutics. The service provides specialized scientific expertise in protein formulation design, optimization, and development to support drug development programs.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Peers10 records
TypeBroad incumbent
Description

Global biologics CDMO offering end-to-end services from cell line development through commercial GMP manufacturing, formulation, and fill-finish for monoclonal antibodies and recombinant proteins. A broad incumbent that competes with Integrity Bio for protein formulation and biologics manufacturing programs.

TypeBroad incumbent
Description

One of the world's largest CDMOs with deep biologics capabilities spanning mammalian and microbial process development, GMP manufacturing, formulation, and fill-finish. Relevant broad incumbent competing for protein formulation programs across all stages of development and serving many of the same biopharma clients.

TypeBroad incumbent
Description

Large global CDMO with biologics, cell and gene therapy, and sterile fill-finish capabilities. Comparable as a broad incumbent that bundles protein formulation and drug product services for biopharma customers, often competing for the same formulation programs as Integrity Bio.

TypeBroad incumbent
Description

Integrity Bio's parent company and the most direct strategic counterparty. Curia is a global CDMO with 20+ facilities, 3,000+ professionals, and an integrated platform spanning small molecule, generic APIs, biologics, and sterile drug product. It is highly comparable because Integrity Bio's protein formulation work sits inside Curia's broader biologics offering and benefits from shared capabilities (mammalian GMP, mRNA/LNP, analytical services).

TypeBroad incumbent
Description

Large-scale biologics CDMO with extensive mammalian cell culture GMP capacity, process development, and aseptic fill-finish. Comparable as a broad incumbent in protein biologics manufacturing and formulation, particularly for late-stage and commercial programs.

TypeDirect peer
Description

Specialized CDMO focused on complex biologics including viral vaccines, gene therapies, and protein-based therapeutics, with process development, GMP manufacturing, and fill-finish. Comparable as a similarly-sized, specialized biologics CDMO competing for similar protein and complex biologic formulation programs.

TypeDirect peer
Description

Biologics-focused CDMO offering antibody/protein discovery, cell line development, process development, analytical, and bioconjugation services. Comparable to Integrity Bio as a biologics specialty CDMO with development-stage service offerings in protein therapeutics.

TypeDirect peer
Description

Global biologics CDMO offering mammalian cell line development, process development, GMP manufacturing, and formulation/fill-finish for proteins, antibodies, and other biologics. Directly comparable to Integrity Bio's protein formulation and bioprocess development focus, serving overlapping biopharma clients.

TypeEmerging player
Description

Growing biologics CDMO with mammalian cell culture, process development, GMP manufacturing, and fill-finish capabilities, expanding internationally from its Taiwan base. Comparable as an emerging biologics-focused CDMO competing in protein formulation and bioprocess development.

TypeDirect peer
Description

U.S.-based biologics CDMO (part of the Hepalink group) providing microbial and mammalian process development, GMP manufacturing, and aseptic fill-finish for proteins and other biologics. Closely comparable in scale and service scope to Integrity Bio, with overlapping protein formulation and bioprocess offerings.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Integrity Bio

Biopharmaceutical Formulation Servicesintegritybio.com

Integrity Bio is a privately held Camarillo, California-based biopharmaceutical services firm founded in 2003, specializing in protein formulation development for biotech and pharma clients, with 101–250 employees and founder-led scientific leadership.

What Integrity Bio does

Integrity Bio is a privately held US biopharmaceutical services company headquartered in Camarillo, California, founded in 2003. The firm positions itself as a leader in protein formulation development, operating in a narrow specialty niche within the broader contract development and manufacturing (CDMO) services landscape. With 101–250 employees, Integrity Bio is mid-sized relative to large integrated CDMOs and competes on scientific depth in protein formulation rather than on end-to-end platform breadth.

The company's core offering centers on protein formulation development services for biopharma clients, a discipline that requires specialized expertise in protein stability, characterization, and delivery. Leadership comprises Michael Reilly as Chief Executive Officer and Byeong Chang as Founder and Chief Scientific Officer, indicating a founder-led scientific governance model with the founder retained in a senior technical role—an arrangement typical of specialist services firms that compete on accumulated technical know-how. The company is privately held with no public listing, no disclosed parent company, and no recorded subsidiaries in the provided data.

The business model follows a professional services / contract services pattern standard to biopharma formulation providers: revenue is generated through project-based formulation development engagements with biotech and pharmaceutical clients. The company maintains a single disclosed site in Camarillo and does not advertise a multi-region facility footprint. No customer logos, pricing model, funding history, M&A activity, or product launches are disclosed in the available data, which limits visibility into revenue mechanics, customer mix, and capital structure. The current data set suggests an established, specialist services firm with stable leadership and a defensible technical niche, but the absence of disclosed financials or strategic activity means any growth or expansion assessment is necessarily constrained.

Integrity Bio firmographics

Firmographics
Name
Integrity Bio
Legal name
Curia Global, Inc.
Website
https://integritybio.com
Company type
Private
Founded year
1990
Operating status
Operating
Headcount range
1–10 employees
Short description
Integrity Bio is a privately held Camarillo, California-based biopharmaceutical services firm founded in 2003, specializing in protein formulation development for biotech and pharma clients, with 101–250 employees and founder-led scientific leadership.
Ownership category
akta.pro rank

Integrity Bio industry classification

Industry
Product category
Biopharmaceutical Formulation Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAJAI
Bioprocess Consumables & Reagents (resins, membranes, media components, buffers)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAGAIAG
Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers)
SECONDARYHLAAAJAD
Process Analytical Technology (PAT) & In-Line/At-Line Analytics (spectroscopy, sensors, monitoring)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)

Keywords

  • Protein formulation development
  • Biopharmaceutical contract services
  • Therapeutic protein services
  • Formulation development services
  • Biologics formulation services

Where Integrity Bio is headquartered

Location

Headquarters

HQ city
Camarillo
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Integrity Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

  1. Contract Development and Manufacturing Services: Curia generates revenue through providing integrated CDMO services across drug discovery, development, and manufacturing. Services are contracted on a project basis with clients ranging from early-stage biotech to large pharmaceutical companies. Revenue is derived from service fees, manufacturing fees, and potentially milestone payments.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Integrity Bio product offering

Product offering

Core offering

Integrity Bio is a privately held protein formulation development company that provides specialized contract services to biopharmaceutical clients. Founded in 2003 and based in Camarillo, California, the company focuses on developing formulations for protein-based therapeutics, supporting drug development and manufacturing pipelines for its biopharma customers.

Product overview

Curia Global is a global Contract Development and Manufacturing Organization (CDMO) offering integrated pharmaceutical services across four main verticals: Small Molecule (discovery through manufacturing), Generic APIs, Biologics (discovery through GMP), and Sterile Drug Product. The company operates 20+ facilities across North America, Europe, and India with 3,000+ professionals. Services include specialized offerings such as mRNA/LNP formulation, high potency API manufacturing, fermentation, flow chemistry, and analytical testing. The Fine Chemicals product line includes specialty reagents like T3P and Gemagique polymers.

Differentiator

Problem solved

Functional benefit

Brands

  • Gemagique® AMPS Polymers: Fine chemical polymer product line
  • T3P® Reagent

Products and services

  • Protein Formulation Development Contract service offering focused on protein formulation development for biopharmaceutical clients developing protein-based therapeutics. The service provides specialized scientific expertise in protein formulation design, optimization, and development to support drug development programs.

Companies that use Integrity Bio

Customer profile

Segments1 record

Ideal customer profiles1 record

Integrity Bio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

Integrity Bio partnerships and signals

Strategic signal

Scale indicators4 records

Integrity Bio competitors and assessment

Company assessment

Broad incumbents

  • WuXi Biologics: Global biologics CDMO offering end-to-end services from cell line development through commercial GMP manufacturing, formulation, and fill-finish for monoclonal antibodies and recombinant proteins. A broad incumbent that competes with Integrity Bio for protein formulation and biologics manufacturing programs.
  • Lonza Group: One of the world's largest CDMOs with deep biologics capabilities spanning mammalian and microbial process development, GMP manufacturing, formulation, and fill-finish. Relevant broad incumbent competing for protein formulation programs across all stages of development and serving many of the same biopharma clients.
  • Catalent: Large global CDMO with biologics, cell and gene therapy, and sterile fill-finish capabilities. Comparable as a broad incumbent that bundles protein formulation and drug product services for biopharma customers, often competing for the same formulation programs as Integrity Bio.
  • Curia Global: Integrity Bio's parent company and the most direct strategic counterparty. Curia is a global CDMO with 20+ facilities, 3,000+ professionals, and an integrated platform spanning small molecule, generic APIs, biologics, and sterile drug product. It is highly comparable because Integrity Bio's protein formulation work sits inside Curia's broader biologics offering and benefits from shared capabilities (mammalian GMP, mRNA/LNP, analytical services).
  • Samsung Biologics: Large-scale biologics CDMO with extensive mammalian cell culture GMP capacity, process development, and aseptic fill-finish. Comparable as a broad incumbent in protein biologics manufacturing and formulation, particularly for late-stage and commercial programs.

Direct peers

  • Vibalogics: Specialized CDMO focused on complex biologics including viral vaccines, gene therapies, and protein-based therapeutics, with process development, GMP manufacturing, and fill-finish. Comparable as a similarly-sized, specialized biologics CDMO competing for similar protein and complex biologic formulation programs.
  • Abzena: Biologics-focused CDMO offering antibody/protein discovery, cell line development, process development, analytical, and bioconjugation services. Comparable to Integrity Bio as a biologics specialty CDMO with development-stage service offerings in protein therapeutics.
  • AGC Biologics: Global biologics CDMO offering mammalian cell line development, process development, GMP manufacturing, and formulation/fill-finish for proteins, antibodies, and other biologics. Directly comparable to Integrity Bio's protein formulation and bioprocess development focus, serving overlapping biopharma clients.
  • Cytovance Biologics: U.S.-based biologics CDMO (part of the Hepalink group) providing microbial and mammalian process development, GMP manufacturing, and aseptic fill-finish for proteins and other biologics. Closely comparable in scale and service scope to Integrity Bio, with overlapping protein formulation and bioprocess offerings.

Emerging players

  • Bora Biologics: Growing biologics CDMO with mammalian cell culture, process development, GMP manufacturing, and fill-finish capabilities, expanding internationally from its Taiwan base. Comparable as an emerging biologics-focused CDMO competing in protein formulation and bioprocess development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Integrity Bio social profiles

Digital presence

Integrity Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Integrity Bio leadership team

Management profile

Number of profiles

Profiles2 records

Integrity Bio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Integrity Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Integrity Bio

What does Integrity Bio do?

Integrity Bio is a privately held protein formulation development company that provides specialized contract services to biopharmaceutical clients. Founded in 2003 and based in Camarillo, California, the company focuses on developing formulations for protein-based therapeutics, supporting drug development and manufacturing pipelines for its biopharma customers.

Is Integrity Bio a public or private company?

Integrity Bio is a private company. It is classified as unknown and is currently operating.

When was Integrity Bio founded?

Integrity Bio was founded in 1990. It employs 1 to 10 people.

Where is Integrity Bio based?

Integrity Bio is headquartered in Camarillo, United States, in the North America region.

How does Integrity Bio make money?

One revenue line is on record: contract Development and Manufacturing Services.

Who are Integrity Bio's main competitors?

Broad incumbents on record are WuXi Biologics, Lonza Group, Catalent, Curia Global and Samsung Biologics. Direct peers are Vibalogics, Abzena, AGC Biologics and Cytovance Biologics. Bora Biologics is listed as an emerging player.

Does Integrity Bio have an API?

No public API is recorded for Integrity Bio.

What industry is Integrity Bio in?

Integrity Bio's product category is Biopharmaceutical Formulation Services. Its primary akta.pro industry code is HLAAAJAI, Bioprocess Consumables & Reagents (resins, membranes, media components, buffers), with a secondary code of HLAGAIAG, Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireThe Lipid Nanoparticles (LNPs) CDMO Market is Projected to Grow at a CAGR of 13.8%, During the Period 2022-2030, claims InsightAce AnalyticInsightAce Analytic Pvt. Ltd. released a market assessment report projecting the global Lipid Nanoparticles (LNPs) CDMO market to grow at a CAGR of 13.8% during 2022-2030, driven by increasing mRNA-based vaccine development, nanoparticle medical applications, and rising outsourcing to contract manufacturers. Key market developments include new LNP formulation services launched by eTheRNA Manufacturing, manufacturing partnerships between Cameron Bio and FUJIFILM Diosynth Biotechnologies, capacity expansions by CordenPharma and Evonik, and acquisitions such as Curia's purchase of Integrity Bio. North America is expected to dominate the market due to established healthcare infrastructure and increasing biopharmaceutical clinical trials, while factors such as expensive CMO services and storage concerns may limit growth.VentureBeatIntegrity Bio and LakePharma Become CuriaCuria announced that Integrity Bio and LakePharma have fully transitioned to the Curia brand, reflecting accelerated integration of the two companies acquired in 2021. The combined organization aims to provide comprehensive biologics discovery, development, and manufacturing solutions. Legal entity names will transition immediately.BioSpaceCuria Completes Acquisition of Integrity BioCuria completed its acquisition of Integrity Bio, a formulation and fill-finish organization, adding two California locations. The deal expands Curia's drug product formulation development capabilities and fill-finish network, which includes three center-of-excellence facilities. Integrity Bio will migrate to the Curia brand in the future.CuriaglobalCuria to Acquire Integrity Bio, Expanding Biologic Formulation and Fill-Finish CapabilitiesCuria has entered into a definitive agreement to acquire Integrity Bio, Inc., a privately held formulation and fill-finish organization based in Camarillo, California. This acquisition is intended to expand Curia's biologic formulation capabilities and add West Coast coverage to its existing East Coast and European facilities. The transaction is expected to close in the third quarter, subject to standard closing conditions.PharmiWeb.comCuria to Acquire Integrity Bio, Expanding Biologic Formulation and Fill-Finish CapabilitiesCuria has entered into a definitive agreement to acquire Integrity Bio, a privately held formulation and fill-finish organization based in Camarillo, California. This acquisition expands Curia's capabilities in biologic drug product formulation and manufacturing, adding West Coast coverage to its existing East Coast and European facilities. The transaction is expected to close in the third quarter of 2021, subject to standard closing conditions.